Shikonin, a promising therapeutic drug for osteoarthritis that acts via autophagy activation

• Published in: International immunopharmacology Vol. 106; p. 108563
• Main Authors: Wang, Anquan, Fang, Sheng, Zhong, Lin, Lu, Ming, Zhou, Hongxiang, Huang, Wei, Li, Lei, Gao, Weilu, Yin, Zongsheng
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2022; Elsevier BV
• Subjects: ADAM protein; Aggrecan; Animal tissues; Arthritis; Autophagy; Beclin-1; Biomedical materials; Cartilage; Cartilage diseases; Catabolism; Chloroquine; Chondrocyte; Chondrocytes; Collagen (type II); Degeneration; Flavonoids; Herbal medicine; IL-1β; Matrix metalloproteinase; Matrix metalloproteinases; Metalloproteinase; mRNA; Osteoarthritis; Osteophytes; Sclerosis; Shikonin; Subchondral bone; Thrombospondin; Beclin-1; Chondrocyte; Shikonin; Osteoarthritis; Autophagy
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2022.108563

•Shikonin increases the expression of Aggrecan and Collagen II.•Shikonin inhibits the expression of MMP1 and ADAMTS-5.•Shikonin activates autophagy in IL-1β-induced OA chondrocytes.•Similarly, shikonin also alleviated cartilage degeneration in an OA mouse model.•Shikonin, a promising therapeutic drug for osteoarthritis. Osteoarthritis (OA) is a chronic joint degenerative disease characterised by narrowed articular space, formation of surrounding osteophytes, and subchondral bone sclerosis. OA is caused by cartilage degeneration, which is closely correlated with the disequilibrium of anabolism and catabolism in chondrocytes. Previous studies have revealed that autophagy plays a significant role in maintaining the balance of anabolic and catabolic activities. Thus, targeting autophagy may be a promising therapeutic strategy for OA. Shikonin, a traditional Chinese herbal medicine isolated from flavonoid glucuronide, has drawn focus for its role in activating autophagy. In this study, the mRNA and protein level of a disintegrin and metalloproteinase with thrombospondin motifs-5 and matrix metalloproteinases-1 decreased with shikonin treatment, in the IL-1β-induced OA cell model. On the contrary, IL-1β-induced downregulation of Aggrecan and Collagen II was ameliorated following shikonin treatment. In addition, the upregulation of autophagy-related marker genes Beclin-1 and LC3II/LC3I in chondrocytes indicated that autophagy could be activated upon shikonin treatment. Moreover, shikonin’s promotion of anabolism in chondrocytes through autophagy activation corresponded with the results from the examination using chloroquine, an autophagy inhibitor. OA mouse cartilage tissues were stained with safranin O and fast green dyes. Results were analysed using the Osteoarthritis Research Society International (OARSI) score, and suggested that mice cartilage degeneration was alleviated after shikonin treatment. Altogether, we identified that shikonin might be a novel promising drug for OA treatment.